The global CAR-T cell therapy market for multiple myeloma is witnessing rapid growth, with the United States emerging as the clear leader. In 2025 and 2026, the U.S. is expected to dominate this market due to advanced healthcare infrastructure, regulatory approvals, and significant investments in innovative cancer treatments.
In 2024, the CAR-T cell therapy market for multiple myeloma was valued at USD 3.4 billion. By 2033, it is projected to reach USD 12.6 billion, growing at a CAGR of 15.8% from 2026 to 2033.
The broader global CAR-T cell therapy market is also set for expansion, with estimates showing growth from USD 8.46 billion in 2025 to USD 88.51 billion by 2034, at a CAGR of 29.8%.
The U.S. boasts an advanced healthcare infrastructure and robust clinical research network, positioning it as the top country for CAR-T cell therapy development and adoption.
In 2025, the FDA removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for approved CAR-T therapies. This change has streamlined access for healthcare providers and patients.
Over 32,000 new cases of multiple myeloma are diagnosed annually in the United States alone, driving demand for cutting-edge treatments.
Advancements in CAR-T cell engineering are enhancing efficacy and safety, attracting investment from both pharmaceutical giants and biotech startups.
Abecma (idecabtagene vicleucel): Bristol Myers Squibb’s BCMA-directed therapy is approved for relapsed/refractory multiple myeloma.
Carvykti (ciltacabtagene autoleucel): Johnson & Johnson and Legend Biotech’s CAR-T therapy has demonstrated a 45% reduction in mortality risk over three years.
Anito-cel: Gilead Sciences and Arcellx’s candidate achieved a 97% response rate in clinical trials, with 62% of patients showing complete responses.
The U.S. leads the CAR-T cell therapy market thanks to FDA approvals, research investments, and partnerships between major pharmaceutical companies and biotech innovators.
Countries like China and Japan are catching up with increasing healthcare investments and clinical trials.
With robust clinical pipelines and regulatory support, the U.S. CAR-T cell therapy market for multiple myeloma will remain dominant through 2025 and 2026. Other regions are expected to follow suit as access to these therapies expands globally.
CAR T-Cell Therapies Market Size Skyrockets 29.8% CAGR by 2034 – Towards Healthcare
CAR T-Cell Therapy for Multiple Myeloma Market | 2025-2033 – Market Growth Reports
CAR T-Cell Therapy for Multiple Myeloma Market’s Strategic Roadmap – Data Insights Market
Legend Biotech: J&J-Tied Cancer Drug Cuts Risk Of Death By 45% – Investors.com
Arcellx and Legend Bio Trade Jabs in Multiple Myeloma – Investors.com
The United Kingdom is rapidly emerging as a global leader in artificial intelligence (AI) and machine learning (ML) applications within… Read More
Germany stands at the forefront of Adeno-Associated Virus (AAV) gene therapy in Europe, driven by a robust biotech ecosystem, significant… Read More
The global cryopreservation and platelet storage technologies market is witnessing robust growth, driven by advancements in regenerative medicine, biobanking expansion,… Read More
Artificial Intelligence (AI) is revolutionizing the life sciences sector, driving innovations in drug discovery, clinical trials, diagnostics, and personalized medicine.… Read More
Sustainable manufacturing is rapidly evolving as industries embrace green technologies. At the forefront of this transformation is bioprocessing, which uses… Read More
The contamination detection in pharmaceutical products market is experiencing remarkable growth in 2025. This surge is driven by strict government… Read More